Retatrutide Supplement Protocol
Evidence-based nutrient depletion risks and supplement recommendations for LY3437943 users.
Activates GIP, GLP-1, and glucagon receptors simultaneously, producing greater weight loss than single or dual agonists. Glucagon receptor activation increases energy expenditure and hepatic glucose output; GIP and GLP-1 activation enhances insulin secretion, suppresses appetite, and slows gastric emptying.
Phase 3 clinical trials (TRIUMPH program, as of April 2026). Not yet FDA approved.
Nutrient Depletion Risks
9 nutrients affected by Retatrutide
Reduced caloric intake leads to lower dietary vitamin D. Rapid fat loss releases stored vitamin D but overall status often declines over 6-12 months.
Reduced food intake, especially red meat. GI side effects may further impair absorption.
Delayed gastric emptying may impair B12 absorption. Reduced meat intake compounds risk.
More than 60% of GLP-1RA users consume below estimated requirements for calcium. Rapid weight loss accelerates bone turnover.
Reduced food intake. GI side effects (nausea, diarrhea) may further deplete.
Appetite suppression leads to inadequate protein intake. Lean mass loss is a major concern with rapid weight loss. Glucagon receptor activation may promote protein catabolism, compounding the risk.
Thiamine deficiency increases over time with prolonged caloric restriction. Glucagon-driven glycogenolysis may increase thiamine utilization.
GI side effects (vomiting, diarrhea) can deplete electrolytes
Reduced dietary intake of fatty fish due to appetite suppression
Essential Supplement Stack
Priority-ranked supplements based on depletion evidence
Recommended Additions
Additional supplements based on individual risk factors
Lab Monitoring Schedule
Recommended testing timeline while on this medication
Every 6-12 months depending on results
Drug Interactions
5 known interactions to monitor
Both reduce B12 absorption. Combined use increases B12 deficiency risk significantly.
Further reduces B12 and magnesium absorption
Retatrutide's triple agonism (including glucagon) may cause unpredictable glucose effects requiring insulin dose adjustment
Vitamin K2 supplementation may affect INR
Delayed gastric emptying may alter levothyroxine absorption
Retatrutide-Specific Notes
Important considerations unique to this medication
Retatrutide is a TRIPLE agonist (GIP/GLP-1/glucagon). The glucagon receptor activation may increase metabolic rate but also accelerates glycogenolysis and could affect blood sugar more aggressively than pure GLP-1 agonists. Phase 2 trials showed weight loss of 24.2% at 48 weeks with 12mg dose — the highest of any GLP-1 class drug tested to date. This aggressive weight loss amplifies all nutrient depletion risks. Monitoring should be more frequent in the first 3-6 months.
Glucagon agonism promotes hepatic glucose output, lipolysis, and protein catabolism. This unique mechanism means retatrutide users may face: (1) higher protein/lean mass loss risk than pure GLP-1 users, (2) greater B-vitamin utilization from accelerated energy metabolism, (3) potential blood glucose fluctuations requiring closer monitoring in diabetic patients.
Phase 2 obesity trial (PMID: 37366315): 338 adults, 48 weeks, weight loss up to -24.2% at 12mg. Phase 2a MASLD substudy (PMID: 38858523): 98 participants, liver fat reduction of -82.4% at 12mg. Body composition substudy in T2D (PMID: 40609566): significant fat mass reduction. TRIUMPH Phase 3 program (PMID: 41090431): 4 trials, 5800+ participants evaluating obesity, OSA, and knee OA.
Nausea, vomiting, and diarrhea are common during dose titration. Choose supplement forms that minimize GI distress: sublingual B12, magnesium glycinate (not oxide), iron bisglycinate (not sulfate), calcium citrate (not carbonate).
Take fat-soluble vitamins (D, K2, E) with the largest meal. Take iron separately from calcium and coffee (2+ hours apart). Take magnesium before bed. Take thyroid medications 60+ minutes before retatrutide injection day meal.
Evidence Citations
18 PubMed-indexed studies referenced
Add this protocol to your profile
Your Daily Intelligence and Ask Dose will be personalized for the Retatrutide protocol, including nutrient depletion alerts and interaction warnings.
Sign in required. Your health data stays encrypted and private.
This protocol is for educational purposes only and is not medical advice. Supplement recommendations are adjunctive support, not replacements for prescribed medication. Always consult your prescribing physician before adding supplements to your Retatrutide regimen. Individual needs vary based on health status, diet, and concurrent medications. Scan Dose is not affiliated with any pharmaceutical manufacturer.
Scan Dose does not sell supplements or accept affiliate commissions. All content is independently researched.